Skip to content
GeoClinicalTrials
Back to search

NCT07147751Not yet recruiting

Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach

Official recordSimplified version

Summary

PCNS-DLBCL is a rare extranodal non-Hodgkin lymphoma that primarily affects the brain, spine, or vitreoretinal space. The prognosis for PCNS-DLBCL is significantly worse than that for its systemic counterpart. Understanding how and where this tumor initiates, and how it survives or depends on the microenvironment of the CNS is key to understanding the underlying biology and identifying reliable biomarkers for selecting personalized therapy or for biologically directed therapy that could improve the cure rate of CNS lymphomas.

Inclusion criteria

1. Be an adult immunocompetent patient who received a PCNS-DLBCL diagnosis according to the WHO-HAEM5 criteria between 2018 and 2024. 2. Availability of formalin-fixed paraffin-embedded (FFPE) diagnostic tumor material. 3. Availability of the baseline and follow-up annotations

Exclusion criteria

1. Established immunodeficiency conditions. 2. Secondary CNS localizations of DLBCL 3. Transformed DLBCL

Contacts

The trial team's contact details are shown on request.

See the official trial record
Status
Not yet recruiting
Phase
—
Study type
Observational
Countries
Switzerland, Italy
Sponsor
International Extranodal Lymphoma Study Group (IELSG)(Other)
Protocol no.
IELSG57
Conditions
Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL)
Interventions
—

Locations · 2

  • Bellinzona, SwitzerlandOncology Institute of Southern Switzerland and Institute of Oncology ResearchNot yet recruiting at this site
  • Pavia, ItalyFondazione IRCCS Policlinico San Matteo PaviaNot yet recruiting at this site

In total, worldwide, both sites listed in the registry are planned; recruitment has not opened yet.

Site status per the ClinicalTrials.gov registry (last update posted: June 22, 2026).

This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.

See also

Other versions

These results are indicative and do not replace medical advice — discuss them with your doctor.